martes, 31 de enero de 2012

In vino...dubitas...(II) / Resveratrol, Revidox...y GLAXO / GSK


«El resveratrol es muy interesante,
sí, pero nadie, hoy día,
puede afirmar con la ciencia en la mano
que éste u otro producto
es capaz de alargar la vida»


Dario Acuña Castroviejo/Univ. Granada
El Mundo/Crónica 14 /6/09


"These data suggested this formulation of resveratrol
may only offer minimal efficacy
while having a potential to indirectly exacérbate
a renal complication common
in this patient population,
’’

Claire Brough, Glaxo spokeswoman
The Boston Globe/ Dec.2, 2010



Fueron "boom" en su momento...Aunque mucho antes de todo esto ya despertaban dudas (Dario Acuña Castroviejo dixit)

Y Glaxo (que se interesó y hasta compró Sirtris) también lo supo (más tarde) y decidió...


Aunque muchos científicos son escépticos respecto a las propiedades rejuvenecedoras del resveratrol, ha suscitado un importante interés comercial. GSK compró en 2008 Sirtris, una compañía que trabajaba con este compuesto, por 720 millones de dólares, pero después interrumpió el trabajo en la versión de un fármaco que simulaba su actividad porque los resultados fueron decepcionantes.Una compañía que fabrica resveratrol bajo el nombre de «Longevinex» fue el promotor de la investigación de Das (Dr.Dipak Das), quien aparece en un vídeo vendiendo este compuesto como la próxima «Aspirina».




Destapan a un investigador que difundía falsos beneficios del vino/ABC 13.01.2012

GlaxoSmithKline PLC stopped development of SRT501, a drug designed to mimic the benefits of red wine, saying the medication didn’t work well enough in cancer patients and could worsen kidney damage.
A clinical trial of the compound was halted this year after kidney damage developed in some patients, the company said in May. After reviewing results of the study in multiple myeloma patients, the company dropped the compound, which is also known as resveratrol, said Claire Brough, a Glaxo spokeswoman.

“These data suggested this formulation of resveratrol may only offer minimal efficacy while having a potential to indirectly exacerbate a renal complication common in this patient population,’’ she said by e-mail. “We have are no further plans to develop SRT501.’’

The decision means the London-based company has given up on the leading drug candidate from Cambridge, Mass.-based Sirtris Pharmaceuticals Inc., which Glaxo acquired for $720 million in 2008. Another drug, SRT2104, is being tested in “a number of’’ midstage clinical trials for use against Type 2 diabetes and psoriasis, among other illnesses, Brough said.


Glaxo halts development of Sirtris’s resveratrol

REVIDOX: In vino "dubitas"...? o la "fuente de la eterna juventud"?

Revidox Vs. Resveradox (I)

Semergen&semFYC: Aquelarre en Cantabria...

Ver
Ver

Ver también:


Homeopatía en PHARMACOSERÍAS


Homeopatía es brujería...

Y AstraZeneca 3.000...arr_astra .


AstraZeneca Plc (AZN), the U.K.’s second- biggest drugmaker, is set to announce more job cuts after beginning a cost-cutting program in 2010, the Sunday Times reported today, without citing anyone.
Two years ago, chief executive David Brennan said more than 10,000 jobs would be lost by 2014, the newspaper said. The target may be extended significantly when the company announces its annual results on Feb. 2, the newspaper said. The drugmaker may spend more than $3 billion on buying back shares this year, the paper said, citing analysts.

Ver


Ver también:

‘Axe hovers over AstraZeneca jobs’

ASTRA arrastra al paro...


Menos mal que vamos mal (VI) / Top 10 "Big Pharma" en los Fondos de inversión alternativa ("Hedge Funds")


Drug companies are non-cyclical stocks that do relatively well during bear markets. They used to be growth stocks too. Top pharmaceutical companies had a 7.1% growth rate between 2003 and 2009. However, the average growth rate is expected to fall to 1.3% by 2015. Nevertheless, these stocks yield more than long-term Treasuries. The top three most popular stocks yield around 3.5% annually.

We believe these stocks are great dividend plays and are also likely to deliver capital gains to their investors over the next few years. We use hedge fund positions in each stock as a proxy for each stock’s potential. Our research has shown that the stocks most favored by hedge funds performed better than the market over the past decade. (Más)

Ver anterior:

lunes, 30 de enero de 2012

Humor...es lunes: VENEZUELA / "Silicon country..."










Cerca de 1.500 venezolanas han sumado ya su respaldo a una demanda presentada en la primera semana de enero por un grupo de casi 500 mujeres contra los comercializadores de los implantes franceses PIP (Poly Implants Prothéses) en Venezuela, a quienes exigen compensaciones económicas. (Ver)

Caracas, EFE 16 de enero de 2012


Ver también:

Con tetas (sin silicona) SI hay paraiso...


"Extensión de línea...": El visitador médico que exportó silicona a medio mundo



NOVARTIS: Joe "pone el ojo" en Brasil...Y no es él solo.


Na busca por novos mercados para expandir seus negócios fora do eixo Estados Unidos-Europa, a farmacêutica suíça Novartis decidiu reforçar suas apostas no Brasil. Em entrevista ao Valor, Joe Jimenez, principal executivo global da companhia, disse que o grupo tem grandes planos para o país. "O Brasil é um dos principais países para investimento para a Novartis. A economia está crescendo e vemos o maior acesso da classe média à saúde", afirmou Jimenez, em entrevista por telefone. O executivo contou que assinou, no fim de novembro, uma carta de intenções com o Ministério da Saúde, selando uma importante parceria entre a companhia e governo brasileiro.

Os planos da Novartis para o Brasil incluem a construção de uma fábrica de biotecnologia para a produção de vacinas em Pernambuco, em um aporte estimado entre US$ 400 milhões e US$ 500 milhões, segundo Jimenez. A parceria também prevê a transferência de tecnologia para a produção de medicamentos nas áreas de oncologia, transplantes e neurociência. A Novartis vai reforçar pesquisas no desenvolvimento de produtos para as chamadas doenças tropicais, como dengue e Chagas, além de ampliar seu programa de combate à hanseníase no país.

Jimenez observou que o país tem hoje cerca de 10 mil pacientes atingidos por doença de Chagas e um milhão de pessoas afetadas pela Dengue. "Desenvolvemos pesquisas para novas terapias para essas doenças em nosso Instituto Novartis, em Cingapura, e temos interesse em estabelecer parcerias com entidades governamentais e instituições acadêmicas locais." A companhia também poderá reforçar os programas do governo para o combate a diabetes e hipertensão. "Tivemos um feedback positivo do governo, uma vez que pretendemos desenvolver medicamentos importantes para o Brasil."
(Más)

Y no es él solo...

Del reciente informe: Life sciences cluster report/Global. 2011



Click sobre imagen para ampliar





Ver también:


Novartis: elige Brasil, não Argentina
/ Cristina Kroll

Citario/El dijo que...: Julian Remnant / Deloitte

"...the pharmaceutical R&D sector can do more to work together" said Remnant, noting that it would be desirable for companies to pool their resources in non-competitive areas of R&D to cut cost, remove duplication of work and make the operations of service provider more efficient. "Sharing knowledge on the science behind failed molecules and studies will help improve success rates, and ultimately bring down the cost to develop new medicines"
Julian Remnant/Deloitte

Ver


Ver también:

Pharma needs to collaborate to boost R&D return


DELOITTE: El futuro y las secuelas de la recesión global...

MEPHA regresa a casa.../ Switzerland's Acino grabs more Mepha business from Teva


Teva Pharmaceutical Industries is selling the Latin American and Asian businesses of its Mepha generics unit to Swiss drugmaker Acino.

The deal comes a couple of months after it was announced that Acino was going to buy the Middle East and African business of Cephalon, which had itself just been acquired by Teva. For that deal, Acino was going to pay 60 million euros in cash and 20 million euros in new shares but the total purchase price for the four business operations, plus the Mepha site in Aesch, Switzerland and certain other considerations now amounts to 94 million euros. (Más)

Ver

Article Switzerland's Acino grabs more Mepha business from Teva

MEPHA ya tiene dueño...CEPHALON.


Merckle y Ratiopharm tambien son MEPHA...

domingo, 29 de enero de 2012

Jackson Pollock "cumple" 100 años...

JPollock - Moby dick 1943


La fotografía de Jackson Pollock sirve a John Mack para "sustentar" el comentario a una cita extraida del ensayo Andrew Witty (ahora Sir...) en The Economist ("Research and develop"):


"Art, not just science" is the heading, under which Witty says: "First, we need to recapture the ability to empower creative talent in the discovery phase of r&d by creating an environment in the labs that reflects the fact that discovering a drug is as much an art as it is a process."

Maybe Witty envisions "Jackson Pollock" wannabe lab researchers throwing chemicals against a wall & seeing what sticks?


Al fin y al cabo son muchos los que se "inspiran" en él....





Ocasión para traerlo ahora que Pollock "cumple 100 años"

Levantamos acta: No "tragamos" la S.O.P.A. ahora tampoco ACTA...


ACTA también podría prohibir

la comercialización
de medicinas genéricas vitales,...



Publicado: 25 Enero 2012

La semana pasada, tres millones de nosotros contribuimos a frenar el ataque de EE.UU. a nuestra web. Pero nos enfrentamos a una amenaza aún más grande, y nuestro movimiento global por la libertad de Internet está perfectamente equipado para eliminarla de una vez por todas.

El ACTA es un tratado global que permitiría a las compañías censurar Internet. Negociado en secreto entre un puñado de países ricos y los grandes poderes corporativos, este acuerdo crearía un opaco organismo anti-falsificación que autorizaría la vigilancia, por parte de poderosos intereses privados, de todo lo que hacemos online. Este acuerdo también les permitiría imponer sanciones durísimas, incluyendo penas de prisión, contra cualquier persona que supuestamente perjudicase sus negocios.

En estos momentos la Unión Europea está decidiendo si ratificará el ACTA, y lo cierto es que sin su participación, este ataque global contra la libertad de Internet fracasará. Sabemos que la UE ya se ha opuesto al ACTA con anterioridad, pero algunos miembros del Parlamento Europeo están titubeando. Démosles el empujón que necesitan para rechazar este acuerdo. Firma la petición -- ¡la entregaremos en Bruselas de forma espectacular cuando reunamos 500.000 firmas!


Firma aquí.

EXPANSIÓN 27 enero 2012.

Empezamos bien el año...




Ver también:

Humor (?)...es lunes: S.O.P.A.


Y qué es la S.O.P.A...?

viernes, 27 de enero de 2012

Cinema Paradiso: "Los cabellos de la medusa"






IntraMed presenta su película en su versión completa on line, "Los cabellos de la Medusa".
El video,
realizado bajo el marco teórico de la Medicina Narrativa ha permitido “rescatar la palabra -a menudo silenciada- de los protagonistas de las enfermedades.” En el mismo, los pacientes narran sus historias de vida, constituyéndose en un excelente “documento para comprender el punto de vista de quien padece los síntomas y el estigma de estas enfermedades.”




Ver peli completa

Menos mal que vamos mal...(V) / y "la miés será mucha..."












Y "la miés es (será) mucha..."










Click sobre imagen para ampliar


Y superiores al 4%...





Ver anterior:

Menos mal que vamos mal...(IV) / Lo que se prevé para 2012.

Illumina será de ROCHE...? / 5.700 millones de $


Click sobre imagen para ampliar.

EXPANSION Ver
EL ECONOMISTA Ver






Ver

También:
Roche's Hostile Bid For Illumina Ups Stakes In DNA Tech Race/Forbes

jueves, 26 de enero de 2012

Male Cancer Awareness: Mr. Testicles / James Bum 002 / NEAR NAKED MAN/ Campaña contra el cáncer de intestino, próstata y de testículos




What We Believe
We believe that too many men die of prostate, bowel and testicular cancer because they do not know how to detect the symptoms in the early stages, when treatment would be more effective.

This ignorance is made worse by the prevailing ‘culture of embarrassment’, that discourages men from discussing and resolving problems related to intimate parts of their body.



What We Do


Host awareness raising sessions at male oriented events, places of work and leisure, schools/colleges/universities and other public places.

Raise the profile of our Charity in general via PR and marketing activities, using our characters. In addition, we may choose to support other Charities related to male cancers for specific campaigns..

Ver



We are a young and innovative charity committed to raising awareness of Male Cancers through our champions - Mr. Testicles, James Bum 002 and Near Naked Man. We aim to educate men and their partners the importance of early detection and we hope to build a culture where embarrassment does not prevent them from addressing problems with intimate parts of their bodies.




Mr Testicles is the founding Charity champion for MCAC’s campaign. His job is to raise awareness and reduce embarrassment of Testicular Cancer. His goal is to gain as much support as possible to help educate young men and their partners on the early warning signs of Testicular cancer. His target! Reduce the deaths of Testicular cancer to Zero!!






Lingerie model and page 3 girl Rhian Sugden shows us her raunchy side in this darkly seductive short film shot by world renowned photographer Rankin.
Since launching our new video less than two weeks ago on 14 September 2011, it has reached the one million mark, with over 1,000,000 viewers on YouTube as of 26 September 2011! This is an epic success for Male Cancer Awareness Campaign, the UK's boldest and most daring charity, as it shows that through innovation we can reach the right target audience in order to spread the message that testicular cancer is treatable if caught early! The video was directed by highly acclaimed and esteemed photographer Rankin, featuring the gorgeous glamour model, Rhian Sugden who shows it like it is. See for yourself just why this one minute clip is causing such a stir...

Menos mal que vamos mal...(IV) / Lo que se prevé para 2012.


Esto es lo que para 2012 se prevé...

Luz al fondo del tunel...:Mediados de 2012




Aunque muchos piensan que ...


Y ven ahí el dinero...


Con notas tomadas de :

El sector farmacéutico: en buen estado de salud en 2012


Ver anterior:

Menos mal que vamos mal...(III)